基于残余风险的入组标准与肿瘤大小及淋巴结状态对乳腺癌辅助治疗试验效能估算的比较
该研究在443例早期乳腺癌患者中计算个体化残余风险,并模拟临床试验效能。结果显示,基于肿瘤大小和淋巴结状态的入组标准下,残余风险分布广泛,导致试验效能不稳定;而采用最低残余风险阈值作为入组标准可产生更可靠的效能估算,并可能以更小样本量达到预设效能。
要点
- 基于解剖学风险(肿瘤大小和淋巴结状态)入组时,患者残余风险差异大,试验效能可能不可预测。
- 采用最低残余风险阈值作为入组标准可提高效能估算的可靠性。
- 未来辅助试验可通过基于最小残余风险定义入组来改善成功率并减少样本量。
核心结论
- 基于肿瘤大小和淋巴结状态定义入组标准时,复发残余风险变化大,导致效能估算不稳定。
- 以最低残余风险阈值作为入组标准可产生更可靠的效能计算,并可能以更小样本量达到预设效能。
研究设计与样本
- 研究纳入443例连续早期乳腺癌患者,估算其残余风险,并评估临床试验效能随残余风险分布的变化。
- 进行两组、1:1随机临床试验模拟,比较基于肿瘤大小和淋巴结状态的入组标准与基于最低残余风险阈值的入组标准对效能的影响。
主要发现
- 443例患者(平均年龄56.1岁,标准差12.3,范围23-89)中,328例(74%)基线复发风险超过20%,但调整治疗效果后仅12例(27%)残余风险超过20%。
- 在符合3项正在 accrual 的随机辅助试验的肿瘤大小和淋巴结状态入组标准的患者队列中,残余风险中位数分别为28%(四分位距25%-31%)、22%(15%-28%)和22%(15%-28%),表明试验效能可能不可预测地变化。
- 模拟显示,使用解剖学风险入组标准时,若入组患者残余风险低,即使符合入组要求,试验也可能效能不足。
关键数值与推荐
- 原文未报告具体的残余风险阈值数值或样本量计算公式。
临床怎么用
- 在设计乳腺癌辅助治疗临床试验时,可考虑使用残余风险预测软件计算个体化残余风险,并以最低残余风险阈值作为入组标准,以提高效能估算的可靠性并可能减少所需样本量。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Many large adjuvant clinical trials end up underpowered because of fewer than expected events in the control arm. Ensuring a minimum number of events would result in more informative trials. OBJECTIVE: To calculate individualized residual risk estimates using residual risk prediction software and assess whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations compared with eligibility criteria based on tumor size and nodal status. DESIGN, SETTING, AND PARTICIPANTS: We estimated residual risk in 443 consecutive patients with early-stage breast cancer and assessed clinical trial power as a function of residual risk distribution among the accrued patients. We defined residual risk as the risk of recurrence that remains despite receipt of standard-of-care therapy; this risk is determined by baseline prognostic risk and by the improvement from adjuvant therapy. We performed trial simulations to examine how the power of a 2-arm, 1:1 randomized clinical trial would change as the residual risk distribution of the trial population that met eligibility criteria based on tumor size and nodal status changes. We also simulated trials that use a minimum residual risk value as eligibility criterion. MAIN OUTCOMES AND MEASURES: Residual risk; clinical trial power as a function of residual risk distribution among the patients. RESULTS: In the 443 patients (mean [SD] age, 56.1 [12.3] years; range, 23-89 years), baseline prognostic and residual risks differed substantially: 328 (74%) patients had more than 20% baseline risk of recurrence; however, after adjustment for treatment effect only 12 (27%) had more than 20% residual risk. We assessed residual risk distribution in patient cohorts that met tumor size- and nodal status-based eligibility criteria for 3 currently accruing randomized adjuvant trials; the median residual risks were 28% (interquartile range [IQR], 25%-31%), 22% (IQR, 15%-28%), and 22% (IQR, 15%-28%), respectively, indicating that the power of these trials could vary unpredictably. Simulations showed that trials that use anatomical risk-based eligibility criteria can become underpowered if they accrue patients with low residual risk despite all participants meeting eligibility requirements. Using a minimum required residual risk threshold as eligibility criterion produced more reliable power calculations. CONCLUSIONS AND RELEVANCE: When tumor size and nodal status are used to determine trial eligibility, the residual risk of recurrence can vary broadly, leading to unstable power estimates. The success of future adjuvant trials could be improved by defining patient eligibility based on a minimal residual risk of recurrence, and these trials can achieve a prespecified power with smaller sample sizes.
引用
- Wei W, Kurita T, Hess KR, et al. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018. PMID: 29372234. doi:10.1001/jamaoncol.2017.5092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。